布地奈德、沙丁胺醇、异丙托溴铵联合雾化吸入治疗新生儿毛细支气管炎的疗效观察

Observation on the effect of budesonide, salbutamol, ipratropium bromide joint inhalation in the treatment ofneonatal capillary bronchitis

目的观察布地奈德、沙丁胺醇、异丙托溴铵联合雾化吸入治疗新生儿毛细支气管炎的临床疗效。方法58例毛细支气管炎患儿按数字表法随机分为观察组和对照组，各29例。两组患儿均接受综合治疗，观察组再给予布地奈德0．5mg、沙丁胺醇15mg、异丙托溴铵120μg，用0．9％氯化钠溶液2ml稀释配制。对照组采用0．9％氯化钠溶液2ml，布地奈德0．5mg。由氧气驱动雾化吸入，每天2次，疗程7d。比较两组临床疗效。结果治疗后，治疗组在气促、气喘、哮鸣音、湿哕音指标均明显优于对照组（t=6．25、3．91、3．76、3．21，均P〈0．01）；观察组总有效率为96．5％，明显高于对照组的93．1％（X^2=6．89，P〈0．05）；两组均未发现明显不良反应。结论布地奈德、沙丁胺醇、异丙托溴铵联合雾化吸人治疗新生儿毛细支气管炎疗效明确，可以减轻咳嗽、喘憋症状，适合临床进一步推广与应用。

Objective To observe the clinical effect of budesonide,salbutamol,ipratropium bromide joint in- halation in the treatment of neonatal capillary bronchitis. Methods According to the digital table, 58 neonates with capillary bronchitis were randomly divided into the observation group and the control group, each group 29 cases. The patients in the two groups were given comprehensive treatment. The observation group was given budesonide 0.5mg, salbutamol 15mg and ipratropium bromide 120μg, which were formulated with 2ml 0.9% sodium chloride solution. The control group received 0.5mg budesonide in 2ml 0.9% sodium chloride solution. The drug was compressed by air pump in the form of aerosol inhalation,2 times every day,which lasted 7 days. The clinical efficacy of the two groups was compared. Results After the treatment, the indicators such as shortness of breath, asthma, wheezing sound, wet sound in observation group were significantly better than those in control group（t =6.25,3.91,3.76,3.21 ,all P 〈 0. 01 ）. The total efficiency of observation group was 96.5%, which was significantly higher than that of the control group of 93. 1% （ X^2 = 6. 89, P 〈 0. 05 ）. No significant adverse reaction were found in the two groups. Conclusion Budesonide, salbutamol,ipratropium bromide joint inhalation in the treatment of neonatal capillary bron- chitis has definite effect, and can relieve coughing, wheezing symptoms, and improve the efficiency, and it is worthy of further clinical promotion and application.